Rituximab for the treatment of rheumatoid arthritis: an update.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsImmunosuppressive agents are associated with peptic ulcer bleedingB-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance TreatmentBifunctional Peptide Inhibitors Suppress Interleukin-6 Proliferation and Ameliorates Murine Collagen-Induced ArthritisCollagen epitope expression on B cells is sufficient to confer tolerance to collagen-induced arthritisProgressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients.Efficacy and safety of rituximab in rheumatic diseases.Past, present, and future for biologic intervention in atopic dermatitis.Mycophenolate mofetil for lupus nephritis: an update.Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.Current perspective on rituximab in rheumatic diseases.Biological Response Modifiers in Rheumatoid Arthritis: Systematic Review and Meta-analysis of SafetyIs an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al.Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.Biosimilars Have Arrived: Rituximab.
P2860
Q26738810-2D84F9F5-0E97-4B00-8354-33CDEAA0E931Q33724127-CBAEC999-9359-4D93-93EB-9049A2B43A9CQ35680023-70C16643-C56A-4479-9C23-A17A4067941CQ35915683-E8063AEE-6551-429E-ACEA-0918C299903DQ36052152-372FFAAC-6008-476B-A85E-C2B5A32568C8Q36715809-9789C4AA-9A00-42DE-A5E8-9A3E267955BFQ37138974-03B58BC2-287E-4592-A6C2-4ADA92418DCCQ37530709-3B8ABFBE-9B1F-4936-AB50-1F185299F0D3Q38353577-96CD18C5-0662-4ACF-97D9-C998EB8A9955Q38423474-59EED475-2D4D-40A8-BFFA-A402D4474C4FQ38585887-49612790-FD3A-47EE-A239-03CAF99CADC3Q38648469-F20B68EE-306E-4E36-AFB8-BB88A61CC2BEQ42373160-CC4FCAD2-526F-4861-A980-E00CCF223AD1Q42654704-EC4A0E79-760C-4776-AEB4-20CE6EE2C5CEQ45765360-AAD0C240-39C8-4492-AA9A-E8F139A48339Q50214755-5C6C99A4-CFF1-4F78-A9FE-57125B9FBC0BQ50323773-DB4E75D7-AB0F-46B9-A9E7-8EE84455BBE4Q55105693-D3B2D67C-9DCE-4CA0-886D-45ED3639F4C3
P2860
Rituximab for the treatment of rheumatoid arthritis: an update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rituximab for the treatment of rheumatoid arthritis: an update.
@en
Rituximab for the treatment of rheumatoid arthritis: an update.
@nl
type
label
Rituximab for the treatment of rheumatoid arthritis: an update.
@en
Rituximab for the treatment of rheumatoid arthritis: an update.
@nl
prefLabel
Rituximab for the treatment of rheumatoid arthritis: an update.
@en
Rituximab for the treatment of rheumatoid arthritis: an update.
@nl
P2860
P921
P356
P1476
Rituximab for the treatment of rheumatoid arthritis: an update.
@en
P2093
Chi Chiu Mok
P2860
P304
P356
10.2147/DDDT.S41645
P407
P5008
P577
2013-12-27T00:00:00Z